Postoperative [
Humans
Male
Female
Middle Aged
Positron Emission Tomography Computed Tomography
Meningioma
/ diagnostic imaging
Prognosis
Gallium Radioisotopes
Progression-Free Survival
Prospective Studies
Neoplasm Recurrence, Local
/ diagnostic imaging
Meningeal Neoplasms
/ diagnostic imaging
World Health Organization
Retrospective Studies
Organometallic Compounds
Extent of resection
Meningioma
PET
Radiotherapy planning
Recurrence
Somatostatin receptor
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
23
04
2023
accepted:
12
08
2023
medline:
29
11
2023
pubmed:
29
8
2023
entrez:
29
8
2023
Statut:
ppublish
Résumé
Tumor resection represents the first-line treatment for symptomatic meningiomas, and the extent of resection has been shown to be of prognostic importance. Assessment of tumor remnants with somatostatin receptor PET proves to be superior to intraoperative estimation with Simpson grading or MRI. In this preliminary study, we evaluate the prognostic relevance of postoperative PET for progression-free survival in meningiomas. We conducted a post hoc analysis on a prospective patient cohort with resected meningioma WHO grade 1. Patients received postoperative MRI and [ We included 46 patients with 49 tumors. The mean age at diagnosis was 57.8 ± 1.7 years with a male-to-female ratio of 1:1.7. Local tumor progression occurred in 7/49 patients (14%) after a median follow-up of 52 months. Positive PET was associated with an increased risk for progression (*p = 0.015) and a lower progression-free survival (*p = 0.029), whereas MRI was not. 20 out of 20 patients (100%) with negative PET findings remained recurrence-free. The location of recurrence/progression on MRI was adjacent to regions where postoperative PET indicated tumor remnants in all cases. Gross tumor volumes were higher on PET compared to MRI (*p = 0.032). Our data show that [
Identifiants
pubmed: 37642702
doi: 10.1007/s00259-023-06400-3
pii: 10.1007/s00259-023-06400-3
pmc: PMC10684417
doi:
Substances chimiques
1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
1HTE449DGZ
Gallium Radioisotopes
0
Organometallic Compounds
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
206-217Informations de copyright
© 2023. The Author(s).
Références
J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39
pubmed: 13406590
Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):870-880
pubmed: 31492994
J Nucl Med. 2017 Oct;58(10):1580-1587
pubmed: 28450556
Orbit. 2015 Feb;34(1):16-22
pubmed: 25264824
J Clin Oncol. 2021 Dec 1;39(34):3839-3852
pubmed: 34618539
J Neurosurg. 2016 Sep;125(3):551-60
pubmed: 26824369
Cancers (Basel). 2022 Sep 13;14(18):
pubmed: 36139596
J Nucl Med. 2020 Sep;61(9):1294-1299
pubmed: 32005771
Neurooncol Adv. 2021 Aug 20;3(1):vdab114
pubmed: 34704034
Neuro Oncol. 2019 Jan 14;21(Suppl 1):i44-i61
pubmed: 30649491
J Neurosurg. 2017 Jan;126(1):201-211
pubmed: 27058201
Int J Radiat Oncol Biol Phys. 2022 Jul 15;113(4):859-865
pubmed: 35460804
Acta Neurochir (Wien). 2022 Jan;164(1):229-238
pubmed: 34714434
Neuro Oncol. 2021 Nov 2;23(11):1821-1834
pubmed: 34181733
Neuro Oncol. 2023 Jan 5;25(1):137-145
pubmed: 35657335
Sci Rep. 2020 Jul 8;10(1):11220
pubmed: 32641701
Cancers (Basel). 2022 Jun 14;14(12):
pubmed: 35740591
Eur J Nucl Med Mol Imaging. 2012 Sep;39(9):1409-15
pubmed: 22669255
Diagnostics (Basel). 2022 Jul 08;12(7):
pubmed: 35885570
Neuro Oncol. 2019 Jan 14;21(Suppl 1):i18-i31
pubmed: 30649489
Cancers (Basel). 2022 Apr 15;14(8):
pubmed: 35454912
Ann Pathol. 2022 Oct;42(5):367-382
pubmed: 34865882
Front Oncol. 2020 Sep 03;10:1633
pubmed: 33014821
Neuro Oncol. 2019 Jul 11;21(7):901-910
pubmed: 31158293
Indian J Nucl Med. 2019 Oct-Dec;34(4):278-283
pubmed: 31579356
Lancet Oncol. 2017 May;18(5):682-694
pubmed: 28314689
J Nucl Med. 2015 Mar;56(3):347-53
pubmed: 25635133
EJNMMI Radiopharm Chem. 2022 Sep 5;7(1):22
pubmed: 36064987
Nat Rev Neurol. 2018 Feb;14(2):106-115
pubmed: 29302064
J Neurosurg. 2020 Oct 23;:1-9
pubmed: 33096534
Radiat Oncol. 2021 Aug 16;16(1):151
pubmed: 34399805
Clin Nucl Med. 2021 Aug 1;46(8):667-668
pubmed: 33782306
Neuro Oncol. 2022 Nov 2;24(11):1815-1826
pubmed: 35674736
Neuro Oncol. 2022 Oct 5;24(Suppl 5):v1-v95
pubmed: 36196752
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Neuro Oncol. 2019 Jan 1;21(1):26-36
pubmed: 30137421
Clin Cancer Res. 2021 Apr 15;27(8):2216-2225
pubmed: 33526423
Radiother Oncol. 2004 Apr;71(1):85-90
pubmed: 15066300
J Clin Neurosci. 2016 Sep;31:37-46
pubmed: 27338209
Pharmaceuticals (Basel). 2021 Jul 20;14(7):
pubmed: 34358127
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
World Neurosurg. 2011 Dec;76(6):564-71
pubmed: 22251505
World Neurosurg. 2016 Dec;96:483-488
pubmed: 27637164
Magn Reson Imaging. 2013 Jul;31(6):923-9
pubmed: 23453762
Neurosurgery. 2020 Dec 15;88(1):140-146
pubmed: 32827256